UCP-LFA Multi-Biomarker Signature (Antibody and Cytokine)

A lateral flow assay developed at Leiden University Medical Center. It uses upconverting reporter particles to quantify anti-PGL-I IgM together with the host proteins IP-10, CRP, CCL4, S100A12 and ApoA1 on one strip, from serum, plasma or a finger-prick sample.

Technology

Host Response · Quantitative lateral flow

What it measures

Anti-PGL-I IgM with the host proteins IP-10, CRP, CCL4, S100A12 and ApoA1

Developer

Leiden University Medical Center (LUMC), Leiden, the Netherlands

Specimen

Capillary blood

Development status

LDT with clinical validation

Regulatory status

None / RUO

Intended use

Combined pathogen and host marker profiling for infection detection and risk stratification

Main limitation

Host markers are not specific to leprosy, and prospective validation is still under way.

Availability

Research prototype at Leiden University Medical Center (van Hooij et al., 2021).

Linked publications

9

Collaborating institutions

The Leprosy Mission International Bangladesh, Erasmus MC (Rotterdam, the Netherlands), Federal University of Pará (Brazil), Armauer Hansen Research Institute (Addis Ababa, Ethiopia), Beijing Tropical Medicine Research Institute (China), Guizhou Provincial Center for Disease Control and Prevention (China), Colorado State University (Fort Collins, CO, USA)

TPP-1, confirming leprosy

42.5 of 100, partial alignment

TPP-2, infection in contacts

39.0 of 100, partial alignment

All 37 tests · Home